What Happened?
, -based Xilio Therapeutics Promoted Christopher Frankenfield as Chief Financial Officer
About the Company
Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company`s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
About the Person
Christopher Frankenfield is Chief Financial Officer at Xilio Therapeutics. Previously, Christopher held various senior HR leadership roles in the industry.
Info Source
News
Short Profile